LP
FATE icon

LMR Partners’s Fate Therapeutics FATE Stock Holding History

LMR Partners’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,838
Closed -$355K – 1163
2022
Q3 		$355K Buy
15,838
+7,749
+96% +$224K 0.01% 939
2022
Q2 		$200K Buy
+8,089
New +$223K ﹤0.01% 1063

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LMR Partners's FATE Position: Q4 2022 in Review

LMR Partners sold out of Fate Therapeutics (FATE) in Q4 2022, closing a stake of 15,838 shares — an estimated $355K sold.

LMR Partners first reported a position in FATE in Q2 2022 and held it in 2 quarters. The position peaked at $355K in Q3 2022. 227 funds tracked by Wall St. Rank hold FATE as of Q4 2022.

  • LMR Partners reported no remaining Fate Therapeutics position as of Q4 2022 after selling out during the quarter.
  • LMR Partners sold 15,838 Fate Therapeutics shares in Q4 2022, an estimated $355K.
  • LMR Partners first reported a position in Fate Therapeutics in Q2 2022 and held it in 2 quarters.
  • LMR Partners's Fate Therapeutics position peaked at $355K in Q3 2022.
  • 227 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2022.

Based on LMR Partners's 13F filing for Q4 2022, filed 14 Feb 2023.